Results 61 to 70 of about 4,142 (167)

S1‐Leitlinie: Therapie der generalisierten pustulösen Psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1669-1678, November 2026.
Zusammenfassung Die S1‐Leitlinie „Therapie der generalisierten pustulösen Psoriasis (GPP)“ ist eine deutsche Leitlinie, die nach den Kriterien der AWMF erstellt wurde. In der Langfassung werden Aspekte wie klinisches Bild, Pathogenese, Diagnose und Differenzialdiagnose, Begleiterkrankungen und Therapien beleuchtet.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors

Drugs - Real World Outcomes
Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food and Drug ...
Jessica A. Walsh, Iris Lin, Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Emond, Louise H. Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D. Chakravarty, Philip Mease   +11 more
doaj   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1669-1678, November 2026.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

Journal of Immunology Research, 2020
Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods. A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs).
Jing Yang, Zongming Wang, Xilin Zhang
doaj   +1 more source

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Linda Stein Gold, April W. Armstrong, Ronald B. Vender, Jennifer Soung, Andrew E. Pink, Joseph Cafone, Bassey Effiom Edem, Ofelia Reyes‐Servin, Jingzhi Jiang, Kellen Cresswell, Cynthia M. C. DeKlotz, Megan Miller‐Kassamali, Ya‐Wen Yang, Mark G. Lebwohl   +13 more
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1831-1839, November 2026.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

ACR Open Rheumatology
Objective Group‐level analyses from the phase 3 DISCOVER‐2 trial of guselkumab demonstrated robust and durable improvements across psoriatic arthritis (PsA) domains.
Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes   +11 more
doaj   +1 more source

Guselkumab Treatment ADHEREnce in BulGaria of Patients with Psoriasis—ADHERE-BG Study

Dermatology and Therapy
Introduction Treatment adherence is crucial for managing chronic diseases, including plaque psoriasis. In Bulgaria, patients with plaque psoriasis can receive treatment with reimbursed biologics, such as guselkumab, if they meet National Health Insurance
Grisha S. Mateev, Zdravka V. Demerdjieva, Rumyana K. Yankova, Klimentina D. Gospodinova, Boryana E. Ilieva, Razvigor B. Darlenski   +5 more
doaj   +1 more source

Guselkumab

Annales de Dermatologie et de Vénéréologie, 2019
  +6 more sources

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study

Indian Journal of Dermatology
Background: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.
Xiuqiu Lin, Min Ou, Yang Li, Junjie Lin, Yunling Yan, Xiaohua Wang   +5 more
doaj   +1 more source